Luca Jacopo Pavan1, Danoob Dalili2,3, Aldo Eros De Vivo4, Arthur Hamel-Senecal5, Federico Torre5, Alexandre Rudel5, Luigi Manfré4, Nicolas Amoretti5. 1. Department of Diagnostic and Interventional Radiology, Nice University Hospital, Hôpital Pasteur 2, Nice, France. lucajpavan@gmail.com. 2. South West London, Elective Orthopaedic Centre (SWLEOC), Epsom, KT18 7EG, London, UK. 3. Department of Radiology, Epsom & St Helier University Hospitals NHS Trust, Dorking Road, Epsom, KT18 7EG, Surrey, UK. 4. Department of Radiology, IOM Mediterranean Oncology Institute, Viagrande, CT, Italy. 5. Department of Diagnostic and Interventional Radiology, Nice University Hospital, Hôpital Pasteur 2, Nice, France.
Abstract
PURPOSE: To evaluate clinical and radiological outcomes of a series of patients treated with a removable percutaneous interspinous process spacer (IPS) (LobsterProject® Techlamed®) for symptomatic degenerative lumbar spinal stenosis (DLSS). METHODS: All patients treated in two centres with this IPS during 2019 were retrospectively reviewed. Procedures were performed under deep sedation or general anaesthesia by two interventional radiologists. Patients were clinically evaluated before intervention and at 3-month follow-up with Visual Analog Scales for pain (VAS), Oswestry Disability Index (ODI) and radiologically with MRI or CT scans. Neural foramina were independently measured for each patient on pre- and post-procedural CT scans by two radiologists. RESULTS: Fifty-nine patients were treated in the selected period of which fifty-eight had complete documentation (mean age 71.2 ± 9.2 years [55-92], 32 males, 26 females). Forty-eight interventions were performed under deep sedation and ten under general anaesthesia, without procedural complications. Clinical follow-up at 3 months showed a significant reduction of pain (VAS from 83 ± 9 to 29 ± 19, - 65%; p < 0.001) and an improvement in functional outcomes (ODI from 31 ± 12 to 13 ± 10%, - 58%; p < 0.001). There was one case of unsatisfactory positioning post procedure, two cases of posterior migration at 3-month follow-up and one case of spinous process fracture. Mean neural foramina area increased from 77 ± 23 to 95 ± 27 mm2 (+ 26%; p < 0.001) with very good inter-observer reliability (Cronbach's alpha = 0.899). CONCLUSION: Percutaneous minimally invasive insertion of a removable IPS device demonstrates a favourable safety profile, good clinical outcomes at 3 months, and apparent anatomical increase in foraminal dimensions. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05203666-Release Date: 21st January 2022, retrospectively registered.
PURPOSE: To evaluate clinical and radiological outcomes of a series of patients treated with a removable percutaneous interspinous process spacer (IPS) (LobsterProject® Techlamed®) for symptomatic degenerative lumbar spinal stenosis (DLSS). METHODS: All patients treated in two centres with this IPS during 2019 were retrospectively reviewed. Procedures were performed under deep sedation or general anaesthesia by two interventional radiologists. Patients were clinically evaluated before intervention and at 3-month follow-up with Visual Analog Scales for pain (VAS), Oswestry Disability Index (ODI) and radiologically with MRI or CT scans. Neural foramina were independently measured for each patient on pre- and post-procedural CT scans by two radiologists. RESULTS: Fifty-nine patients were treated in the selected period of which fifty-eight had complete documentation (mean age 71.2 ± 9.2 years [55-92], 32 males, 26 females). Forty-eight interventions were performed under deep sedation and ten under general anaesthesia, without procedural complications. Clinical follow-up at 3 months showed a significant reduction of pain (VAS from 83 ± 9 to 29 ± 19, - 65%; p < 0.001) and an improvement in functional outcomes (ODI from 31 ± 12 to 13 ± 10%, - 58%; p < 0.001). There was one case of unsatisfactory positioning post procedure, two cases of posterior migration at 3-month follow-up and one case of spinous process fracture. Mean neural foramina area increased from 77 ± 23 to 95 ± 27 mm2 (+ 26%; p < 0.001) with very good inter-observer reliability (Cronbach's alpha = 0.899). CONCLUSION: Percutaneous minimally invasive insertion of a removable IPS device demonstrates a favourable safety profile, good clinical outcomes at 3 months, and apparent anatomical increase in foraminal dimensions. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05203666-Release Date: 21st January 2022, retrospectively registered.
Authors: Richard A Deyo; Darryl T Gray; William Kreuter; Sohail Mirza; Brook I Martin Journal: Spine (Phila Pa 1976) Date: 2005-06-15 Impact factor: 3.468
Authors: Joshua C Richards; Sharmila Majumdar; Derek P Lindsey; Gary S Beaupré; Scott A Yerby Journal: Spine (Phila Pa 1976) Date: 2005-04-01 Impact factor: 3.468
Authors: Stefano Marcia; Joshua A Hirsch; Ronil V Chandra; Mariangela Marras; Emanuele Piras; Giovanni Carlo Anselmetti; Mario Muto; Luca Saba Journal: J Vasc Interv Radiol Date: 2015-06-26 Impact factor: 3.464
Authors: Luigi Manfre; Aldo Eros De Vivo; Hosam Al Qatami; Ahmed Own; Fausto Ventura; Kevin Zhou; Ronil V Chandra; Joshua A Hirsch Journal: J Neurointerv Surg Date: 2020-01-22 Impact factor: 5.836
Authors: Jan Van Meirhaeghe; Patrick Fransen; Daniele Morelli; Niall J A Craig; Gregor Godde; Attila Mihalyi; Frederic Collignon Journal: Eur Spine J Date: 2012-05-08 Impact factor: 3.134
Authors: Laxmaiah Manchikanti; Alan David Kaye; Kavita Manchikanti; Mark Boswell; Vidyasagar Pampati; Joshua Hirsch Journal: Anesth Pain Med Date: 2015-02-01